| Year |
Citation |
Score |
| 2024 |
Fan Z, Pavlova A, Jenkins MC, Bassit L, Salman M, Lynch DL, Patel D, Korablyov M, Finn MG, Schinazi RF, Gumbart JC. Biophysics-Guided Lead Discovery of HBV Capsid Assembly Modifiers. Acs Infectious Diseases. 10: 1162-1173. PMID 38564659 DOI: 10.1021/acsinfecdis.3c00479 |
0.681 |
|
| 2024 |
Amblard F, LeCher JC, De R, Zhou S, Liu P, Goh SL, Tao S, Patel D, Downs-Bowen J, Zandi K, Zhang H, Chaudhry G, McBrayer T, Muczynski M, Al-Homoudi A, ... ... Schinazi RF, et al. Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease. European Journal of Medicinal Chemistry. 268: 116263. PMID 38432056 DOI: 10.1016/j.ejmech.2024.116263 |
0.659 |
|
| 2024 |
Dinh T, Tber Z, Rey JS, Mengshetti S, Annamalai AS, Haney R, Briganti L, Amblard F, Fuchs JR, Cherepanov P, Kim K, Schinazi RF, Perilla JR, Kim B, Kvaratskhelia M. The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir. Biorxiv : the Preprint Server For Biology. PMID 38328097 DOI: 10.1101/2024.01.26.577387 |
0.328 |
|
| 2023 |
Amblard F, Chen Z, Wiseman J, Zhou S, Liu P, Salman M, Verma K, Azadi N, Downs-Bowen J, Tao S, Kumari A, Zhang Q, Smith DB, Patel D, Bassit L, ... Schinazi RF, et al. Synthesis and evaluation of highly potent HBV capsid assembly modulators (CAMs). Bioorganic Chemistry. 141: 106923. PMID 37871391 DOI: 10.1016/j.bioorg.2023.106923 |
0.681 |
|
| 2023 |
Bassit L, Amblard F, Patel DJ, Biteau N, Chen Z, Kasthuri M, Zhou S, Schinazi RF. The Premise of Capsid Assembly Modulators Towards Eliminating HBV Persistence. Expert Opinion On Drug Discovery. PMID 37477111 DOI: 10.1080/17460441.2023.2239701 |
0.661 |
|
| 2023 |
Biteau NG, Amichai SA, Azadi N, De R, Downs-Bowen J, Lecher JC, MacBrayer T, Schinazi RF, Amblard F. Synthesis of 4'-Substituted Carbocyclic Uracil Derivatives and Their Monophosphate Prodrugs as Potential Antiviral Agents. Viruses. 15. PMID 36851758 DOI: 10.3390/v15020544 |
0.32 |
|
| 2022 |
LeCher JC, Zandi K, Costa VV, Amblard F, Tao S, Patel D, Lee S, da Silva Santos FR, Goncalves MR, Queroz-Junior CM, Marim FM, Musall K, Goh SL, McBrayer T, Downs-Bowen J, ... ... Schinazi RF, et al. Discovery of a 2'-Fluoro,2'-Bromouridine Phosphoramidate Prodrug Exhibiting Anti-Yellow Fever Virus Activity in Culture and in Mice. Microorganisms. 10. PMID 36363688 DOI: 10.3390/microorganisms10112098 |
0.656 |
|
| 2022 |
Patel D, Ono SK, Bassit L, Verma K, Amblard F, Schinazi RF. Assessment of a Computational Approach to Predict Drug Resistance Mutations for HIV, HBV and SARS-CoV-2. Molecules (Basel, Switzerland). 27. PMID 36080181 DOI: 10.3390/molecules27175413 |
0.623 |
|
| 2022 |
Amblard F, Patel D, Michailidis E, Coats SJ, Kasthuri M, Biteau N, Tber Z, Ehteshami M, Schinazi RF. HIV nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry. 240: 114554. PMID 35792384 DOI: 10.1016/j.ejmech.2022.114554 |
0.654 |
|
| 2022 |
Mirza MU, Alanko I, Vanmeert M, Muzzarelli KM, Salo-Ahen OMH, Abdullah I, Kovari IA, Claes S, De Jonghe S, Schols D, Schinazi RF, Kovari LC, Trant JF, Ahmad S, Froeyen M. The discovery of Zika virus NS2B-NS3 inhibitors with antiviral activity via an integrated virtual screening approach. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 175: 106220. PMID 35618201 DOI: 10.1016/j.ejps.2022.106220 |
0.303 |
|
| 2022 |
Schinazi RF, Patel D, Ehteshami M. The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir. Antiviral Therapy. 27: 13596535211067599. PMID 35491570 DOI: 10.1177/13596535211067599 |
0.631 |
|
| 2022 |
Patel D, Cox BD, Kasthuri M, Mengshetti S, Bassit L, Verma K, Ollinger-Russell O, Amblard F, Schinazi RF. In silico design of a novel nucleotide antiviral agent by free energy perturbation. Chemical Biology & Drug Design. PMID 35313085 DOI: 10.1111/cbdd.14042 |
0.661 |
|
| 2022 |
Pavlova A, Bassit L, Cox BD, Korablyov M, Chipot C, Patel D, Lynch DL, Amblard F, Schinazi RF, Gumbart JC. The Mechanism of Action of Hepatitis B Virus Capsid Assembly Modulators Can Be Predicted from Binding to Early Assembly Intermediates. Journal of Medicinal Chemistry. PMID 35290049 DOI: 10.1021/acs.jmedchem.1c02040 |
0.669 |
|
| 2021 |
Hanna GS, Choo YM, Harbit R, Paeth H, Wilde S, Mackle J, Verga JU, Wolf BJ, Thomas OP, Croot P, Cray J, Thomas C, Li LZ, Hardiman G, Hu JF, ... ... Schinazi RF, et al. Contemporary Approaches to the Discovery and Development of Broad-Spectrum Natural Product Prototypes for the Control of Coronaviruses. Journal of Natural Products. PMID 34677966 DOI: 10.1021/acs.jnatprod.1c00625 |
0.614 |
|
| 2021 |
Bassit L, Ono SK, Schinazi RF. Moving Fast Toward Hepatitis B Virus Elimination. Advances in Experimental Medicine and Biology. 1322: 115-138. PMID 34258739 DOI: 10.1007/978-981-16-0267-2_5 |
0.373 |
|
| 2021 |
Hurwitz SJ, McBrearty N, Arzumanyan A, Bichenkov E, Tao S, Bassit L, Chen Z, Kohler JJ, Amblard F, Feitelson MA, Schinazi RF. Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator. Viruses. 13. PMID 33467678 DOI: 10.3390/v13010114 |
0.312 |
|
| 2020 |
Amblard F, Boucle S, Bassit L, Chen Z, Sari O, Cox B, Verma K, Ozturk T, Ollinger-Russell O, Schinazi RF. Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents. Bioorganic & Medicinal Chemistry. 31: 115952. PMID 33421915 DOI: 10.1016/j.bmc.2020.115952 |
0.381 |
|
| 2020 |
Bertoletti N, Chan AH, Schinazi RF, Anderson KS. Post-Catalytic Complexes with Emtricitabine or Stavudine and HIV-1 Reverse Transcriptase Reveal New Mechanistic Insights for Nucleotide Incorporation and Drug Resistance. Molecules (Basel, Switzerland). 25. PMID 33096918 DOI: 10.3390/molecules25204868 |
0.307 |
|
| 2020 |
Coggins SA, Kim DH, Schinazi RF, Desrosiers RC, Kim B. Enhanced enzyme kinetics of reverse transcriptase variants cloned from animals infected with SIVmac239 lacking Viral Protein X. The Journal of Biological Chemistry. PMID 33008888 DOI: 10.1074/jbc.RA120.015273 |
0.3 |
|
| 2020 |
Kasthuri M, Li C, Verma K, Russell OO, Dickson L, McCormick L, Bassit L, Amblard F, Schinazi RF. Synthesis of 4'-Substituted-2'-Deoxy-2'-α-Fluoro Nucleoside Analogs as Potential Antiviral Agents. Molecules (Basel, Switzerland). 25. PMID 32168734 DOI: 10.3390/molecules25061258 |
0.339 |
|
| 2019 |
Amblard F, Boucle S, Bassit L, Cox B, Sari O, Tao S, Chen Z, Ozturk T, Verma K, Russell O, Rat V, de Rocquigny H, Fiquet O, Boussand M, Di Santo J, ... ... Schinazi RF, et al. Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses and in Humanized Mice. Antimicrobial Agents and Chemotherapy. PMID 31712213 DOI: 10.1128/AAC.01701-19 |
0.374 |
|
| 2019 |
Bertoletti N, Chan AH, Schinazi RF, Yin YW, Anderson KS. Structural insights into the recognition of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) by HIV-1 reverse transcriptase: First crystal structures with RT and the active triphosphate forms of lamivudine and emtricitabine. Protein Science : a Publication of the Protein Society. PMID 31301259 DOI: 10.1002/Pro.3681 |
0.345 |
|
| 2019 |
Zandi K, Bassit L, Amblard F, Cox BD, Hassandarvish P, Moghaddam E, Yueh A, Libanio Rodrigues GO, Passos I, Costa VV, AbuBakar S, Zhou L, Kohler J, Teixeira MM, Schinazi RF. Nucleoside Analogs with Selective Antiviral Activity Against Dengue Fever and Japanese Encephalitis Viruses. Antimicrobial Agents and Chemotherapy. PMID 31061163 DOI: 10.1128/AAC.00397-19 |
0.352 |
|
| 2018 |
Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV curative therapies. Liver International : Official Journal of the International Association For the Study of the Liver. 38: 102-114. PMID 29427479 DOI: 10.1111/liv.13656 |
0.349 |
|
| 2017 |
Sari O, Boucle S, Cox BD, Ozturk T, Russell OO, Bassit L, Amblard F, Schinazi RF. Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector. European Journal of Medicinal Chemistry. 138: 407-421. PMID 28688280 DOI: 10.1016/j.ejmech.2017.06.062 |
0.317 |
|
| 2017 |
Kuiper BD, Slater K, Spellmon N, Holcomb J, Medapureddy P, Muzzarelli KM, Yang Z, Ovadia R, Amblard F, Kovari IA, Schinazi RF, Kovari LC. Increased activity of unlinked Zika virus NS2B/NS3 protease compared to linked Zika virus protease. Biochemical and Biophysical Research Communications. PMID 28342876 DOI: 10.1016/J.Bbrc.2017.03.108 |
0.332 |
|
| 2017 |
Boucle S, Lu X, Bassit L, Ozturk T, Russell OO, Amblard F, Coats SJ, Schinazi RF. Synthesis and antiviral evaluation of novel heteroarylpyrimidines analogs as HBV capsid effectors. Bioorganic & Medicinal Chemistry Letters. PMID 28094179 DOI: 10.1016/j.bmcl.2017.01.010 |
0.324 |
|
| 2016 |
Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, Li F, Li B, Liu J, Hou J, Sun J, Wang C, Chen J, Wu V, Wong A, ... ... Schinazi RF, et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. The Lancet. Gastroenterology & Hepatology. 1: 97-104. PMID 27917405 DOI: 10.1016/S2468-1253(16)30015-2 |
0.317 |
|
| 2016 |
Mahmoud S, Li H, McBrayer TR, Bassit L, Hammad SF, Coats SJ, Amblard F, Schinazi RF. Synthesis and antiviral evaluation of fluorinated acyclo-nucleosides and their phosphoramidates. Nucleosides, Nucleotides & Nucleic Acids. 1-17. PMID 27759481 DOI: 10.1080/15257770.2016.1218023 |
0.336 |
|
| 2016 |
Boucle S, Bassit L, Ehteshami M, Schinazi RF. Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities. Clinics in Liver Disease. 20: 737-749. PMID 27742011 DOI: 10.1016/j.cld.2016.07.001 |
0.329 |
|
| 2015 |
Gogineni V, Schinazi RF, Hamann MT. Role of Marine Natural Products in the Genesis of Antiviral Agents. Chemical Reviews. 115: 9655-706. PMID 26317854 DOI: 10.1021/Cr4006318 |
0.323 |
|
| 2015 |
Kennedy EM, Bassit LC, Mueller H, Kornepati AV, Bogerd HP, Nie T, Chatterjee P, Javanbakht H, Schinazi RF, Cullen BR. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 476: 196-205. PMID 25553515 DOI: 10.1016/J.Virol.2014.12.001 |
0.311 |
|
| 2014 |
Kohler JJ, Nettles JH, Amblard F, Hurwitz SJ, Bassit L, Stanton RA, Ehteshami M, Schinazi RF. Approaches to hepatitis C treatment and cure using NS5A inhibitors. Infection and Drug Resistance. 7: 41-56. PMID 24623983 DOI: 10.2147/Idr.S36247 |
0.378 |
|
| 2014 |
Kauffman RC, Villalobos A, Bowen JH, Adamson L, Schinazi RF. Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution. Plos One. 9: e88258. PMID 24505452 DOI: 10.1371/journal.pone.0088258 |
0.321 |
|
| 2014 |
Wadford DA, Kauffman RC, Deere JD, Aoki ST, Stanton RA, Higgins J, Van Rompay KK, Villalobos A, Nettles JH, Schinazi RF, Pedersen NC, North TW. Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV. Plos One. 9: e86997. PMID 24498008 DOI: 10.1371/Journal.Pone.0086997 |
0.32 |
|
| 2014 |
Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrobial Agents and Chemotherapy. 58: 1977-86. PMID 24419350 DOI: 10.1128/Aac.02496-13 |
0.327 |
|
| 2014 |
Kesel AJ, Huang Z, Murray MG, Prichard MN, Caboni L, Nevin DK, Fayne D, Lloyd DG, Detorio MA, Schinazi RF. Retinazone inhibits certain blood-borne human viruses including Ebola virus Zaire. Antiviral Chemistry & Chemotherapy. 23: 197-215. PMID 23636868 DOI: 10.3851/Imp2568 |
0.366 |
|
| 2013 |
Bondada L, Detorio M, Bassit L, Tao S, Montero CM, Singletary TM, Zhang H, Zhou L, Cho JH, Coats SJ, Schinazi RF. Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses. Acs Medicinal Chemistry Letters. 4: 747-751. PMID 24015326 DOI: 10.1021/ml4001497 |
0.354 |
|
| 2013 |
Wu G, Liu B, Zhang Y, Li J, Arzumanyan A, Clayton MM, Schinazi RF, Wang Z, Goldmann S, Ren Q, Zhang F, Feitelson MA. Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrobial Agents and Chemotherapy. 57: 5344-54. PMID 23959305 DOI: 10.1128/AAC.01091-13 |
0.346 |
|
| 2013 |
Hamada M, Roy V, McBrayer TR, Whitaker T, Urbina-Blanco C, Nolan SP, Balzarini J, Snoeck R, Andrei G, Schinazi RF, Agrofoglio LA. Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides. European Journal of Medicinal Chemistry. 67: 398-408. PMID 23911854 DOI: 10.1016/J.Ejmech.2013.06.053 |
0.377 |
|
| 2013 |
Amie SM, Daly MB, Noble E, Schinazi RF, Bambara RA, Kim B. Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. The Journal of Biological Chemistry. 288: 20683-91. PMID 23744077 DOI: 10.1074/Jbc.M113.472159 |
0.308 |
|
| 2012 |
Schinazi RF, Bassit L, Clayton MM, Sun B, Kohler JJ, Obikhod A, Arzumanyan A, Feitelson MA. Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrobial Agents and Chemotherapy. 56: 6186-91. PMID 22985879 DOI: 10.1128/AAC.01483-12 |
0.332 |
|
| 2012 |
Gavegnano C, Kennedy EM, Kim B, Schinazi RF. The Impact of Macrophage Nucleotide Pools on HIV-1 Reverse Transcription, Viral Replication, and the Development of Novel Antiviral Agents. Molecular Biology International. 2012: 625983. PMID 22811909 DOI: 10.1155/2012/625983 |
0.322 |
|
| 2012 |
Vanpouille C, Lisco A, Introini A, Grivel JC, Munawwar A, Merbah M, Schinazi RF, Derudas M, McGuigan C, Balzarini J, Margolis L. Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin. Antimicrobial Agents and Chemotherapy. 56: 2604-11. PMID 22314523 DOI: 10.1128/AAC.05986-11 |
0.323 |
|
| 2011 |
van Maarseveen NM, Wensing AM, de Jong D, Beilhartz GL, Obikhod A, Tao S, Pingen M, Arends JE, Hoepelman AI, Schinazi RF, Götte M, Nijhuis M. Telbivudine exerts no antiviral activity against HIV-1 in vitro and in humans. Antiviral Therapy. 16: 1123-30. PMID 22024528 DOI: 10.3851/Imp1912 |
0.301 |
|
| 2011 |
Deere JD, Schinazi RF, North TW. Simian immunodeficiency virus macaque models of HIV latency. Current Opinion in Hiv and Aids. 6: 57-61. PMID 21242894 DOI: 10.1097/Coh.0B013E32834086Ce |
0.306 |
|
| 2010 |
Deere JD, Higgins J, Cannavo E, Villalobos A, Adamson L, Fromentin E, Schinazi RF, Luciw PA, North TW. Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. Plos One. 5: e11640. PMID 20668516 DOI: 10.1371/Journal.Pone.0011640 |
0.33 |
|
| 2010 |
Vanpouille C, Lisco A, Derudas M, Saba E, Grivel JC, Brichacek B, Scrimieri F, Schinazi R, Schols D, McGuigan C, Balzarini J, Margolis L. A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2. The Journal of Infectious Diseases. 201: 635-43. PMID 20085496 DOI: 10.1086/650343 |
0.324 |
|
| 2010 |
North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, Shacklett BL, Schinazi RF, Luciw PA. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. Journal of Virology. 84: 2913-22. PMID 20032180 DOI: 10.1128/Jvi.02356-09 |
0.31 |
|
| 2010 |
Zhang HW, Coats SJ, Bondada L, Amblard F, Detorio M, Asif G, Fromentin E, Solomon S, Obikhod A, Whitaker T, Sluis-Cremer N, Mellors JW, Schinazi RF. Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. Bioorganic & Medicinal Chemistry Letters. 20: 60-4. PMID 19948402 DOI: 10.1016/J.Bmcl.2009.11.031 |
0.329 |
|
| 2009 |
Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW. Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. Antimicrobial Agents and Chemotherapy. 53: 3715-9. PMID 19596885 DOI: 10.1128/Aac.00392-09 |
0.329 |
|
| 2009 |
Tchesnokov EP, Obikhod A, Massud I, Lisco A, Vanpouille C, Brichacek B, Balzarini J, McGuigan C, Derudas M, Margolis L, Schinazi RF, Götte M. Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase. The Journal of Biological Chemistry. 284: 21496-504. PMID 19509419 DOI: 10.1074/Jbc.M109.024026 |
0.306 |
|
| 2009 |
Kim HJ, Sharon A, Bal C, Wang J, Allu M, Huang Z, Murray MG, Bassit L, Schinazi RF, Korba B, Chu CK. Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro. Journal of Medicinal Chemistry. 52: 206-13. PMID 19072694 DOI: 10.1021/Jm801418V |
0.338 |
|
| 2009 |
Schinazi RF, Coats SJ, Bassit LC, Lennerstrand J, Nettles JH, Hurwitz SJ. Approaches for the development of antiviral compounds: the case of hepatitis C virus. Handbook of Experimental Pharmacology. 25-51. PMID 19048196 DOI: 10.1007/978-3-540-79086-0_2 |
0.307 |
|
| 2008 |
Tchesnokov EP, Obikhod A, Schinazi RF, Götte M. Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase. The Journal of Biological Chemistry. 283: 34218-28. PMID 18940786 DOI: 10.1074/Jbc.M806797200 |
0.355 |
|
| 2008 |
Domaoal RA, McMahon M, Thio CL, Bailey CM, Tirado-Rives J, Obikhod A, Detorio M, Rapp KL, Siliciano RF, Schinazi RF, Anderson KS. Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase. The Journal of Biological Chemistry. 283: 5452-9. PMID 17962184 DOI: 10.1074/Jbc.M707834200 |
0.349 |
|
| 2007 |
Feitelson MA, Clayton MM, Sun B, Schinazi RF. Development of a novel mouse model to evaluate drug candidates against hepatitis B virus. Antiviral Chemistry & Chemotherapy. 18: 213-23. PMID 17907379 |
0.324 |
|
| 2007 |
Chun BK, Wang P, Hassan A, Du J, Tharnish PM, Murakami E, Stuyver L, Otto MJ, Schinazi RF, Watanabe KA. Synthesis and biological activity of 5',9-anhydro-3-purine-isonucleosides as potential anti-hepatitis C virus agents. Nucleosides, Nucleotides & Nucleic Acids. 26: 83-97. PMID 17162589 DOI: 10.1080/15257770601052307 |
0.332 |
|
| 2006 |
Rao JR, Schinazi RF, Chu CK. Enantioselective synthesis and antiviral activity of purine and pyrimidine cyclopentenyl C-nucleosides. Bioorganic & Medicinal Chemistry. 15: 839-46. PMID 17085053 DOI: 10.1016/j.bmc.2006.10.043 |
0.311 |
|
| 2006 |
Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie MY, Schinazi RF, Morrey JD, Julander JL, Furman PA, Otto MJ. Inhibition of hepatitis C replicon RNA synthesis by β-D-2′- deoxy-2′-fluoro-2′-C-methylcytidine: A specific inhibitor of hepatitis C virus replication Antiviral Chemistry and Chemotherapy. 17: 79-87. PMID 17042329 DOI: 10.1177/095632020601700203 |
0.326 |
|
| 2006 |
Schinazi RF, Hernandez-Santiago BI, Hurwitz SJ. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses. Antiviral Research. 71: 322-34. PMID 16716415 DOI: 10.1016/j.antiviral.2006.03.012 |
0.37 |
|
| 2006 |
Clark JL, Mason JC, Hollecker L, Stuyver LJ, Tharnish PM, McBrayer TR, Otto MJ, Furman PA, Schinazi RF, Watanabe KA. Synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorganic & Medicinal Chemistry Letters. 16: 1712-5. PMID 16368235 DOI: 10.1016/j.bmcl.2005.12.002 |
0.31 |
|
| 2005 |
Sharma PL, Nurpeisov V, Schinazi RF. Retrovirus reverse transcriptases containing a modified YXDD motif. Antiviral Chemistry & Chemotherapy. 16: 169-82. PMID 16004080 DOI: 10.1177/095632020501600303 |
0.33 |
|
| 2005 |
North TW, Van Rompay KK, Higgins J, Matthews TB, Wadford DA, Pedersen NC, Schinazi RF. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Journal of Virology. 79: 7349-54. PMID 15919889 DOI: 10.1128/Jvi.79.12.7349-7354.2005 |
0.32 |
|
| 2005 |
Ray AS, Hernandez-Santiago BI, Mathew JS, Murakami E, Bozeman C, Xie MY, Dutschman GE, Gullen E, Yang Z, Hurwitz S, Cheng YC, Chu CK, McClure H, Schinazi RF, Anderson KS. Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine. Antimicrobial Agents and Chemotherapy. 49: 1994-2001. PMID 15855524 DOI: 10.1128/AAC.49.5.1994-2001.2005 |
0.35 |
|
| 2005 |
Likhitwitayawuid K, Sritularak B, Benchanak K, Lipipun V, Mathew J, Schinazi RF. Phenolics with antiviral activity from Millettia erythrocalyx and Artocarpus lakoocha. Natural Product Research. 19: 177-82. PMID 15715263 DOI: 10.1080/14786410410001704813 |
0.317 |
|
| 2004 |
Hofman MJ, Higgins J, Matthews TB, Pedersen NC, Tan C, Schinazi RF, North TW. Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 48: 3483-90. PMID 15328115 DOI: 10.1128/Aac.48.9.3483-3490.2004 |
0.351 |
|
| 2004 |
Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Current Topics in Medicinal Chemistry. 4: 895-919. PMID 15134548 DOI: 10.2174/1568026043388484 |
0.377 |
|
| 2004 |
Pankiewicz KW, Patterson SE, Black PL, Jayaram HN, Risal D, Goldstein BM, Stuyver LJ, Schinazi RF. Cofactor mimics as selective inhibitors of NAD-dependent inosine monophosphate dehydrogenase (IMPDH)--the major therapeutic target. Current Medicinal Chemistry. 11: 887-900. PMID 15083807 DOI: 10.2174/0929867043455648 |
0.322 |
|
| 2004 |
Stuyver LJ, McBrayer TR, Whitaker T, Tharnish PM, Ramesh M, Lostia S, Cartee L, Shi J, Hobbs A, Schinazi RF, Watanabe KA, Otto MJ. Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2'-deoxy-2'-fluorocytidine. Antimicrobial Agents and Chemotherapy. 48: 651-4. PMID 14742230 DOI: 10.1128/AAC.48.2.651-654.2004 |
0.325 |
|
| 2004 |
Liu X, Schinazi RF. Hepatitis B virus resistance to lamivudine and its clinical implications. Antiviral Chemistry & Chemotherapy. 13: 143-55. PMID 12448687 DOI: 10.1177/095632020201300301 |
0.342 |
|
| 2003 |
Erickson-Viitanen S, Wu JT, Shi G, Unger S, King RW, Fish B, Klabe R, Geleziunas R, Gallagher K, Otto MJ, Schinazi RF. Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV. Antiviral Chemistry & Chemotherapy. 14: 39-47. PMID 12790515 |
0.332 |
|
| 2002 |
Stuyver LJ, Lostia S, Adams M, Mathew JS, Pai BS, Grier J, Tharnish PM, Choi Y, Chong Y, Choo H, Chu CK, Otto MJ, Schinazi RF. Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues. Antimicrobial Agents and Chemotherapy. 46: 3854-60. PMID 12435688 DOI: 10.1128/AAC.46.12.3854-3860.2002 |
0.32 |
|
| 2002 |
Schinazi RF, Mellors J, Bazmi H, Diamond S, Garber S, Gallagher K, Geleziunas R, Klabe R, Pierce M, Rayner M, Wu JT, Zhang H, Hammond J, Bacheler L, Manion DJ, et al. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrobial Agents and Chemotherapy. 46: 1394-401. PMID 11959574 DOI: 10.1128/Aac.46.5.1394-1401.2002 |
0.328 |
|
| 2002 |
Ray AS, Yang Z, Shi J, Hobbs A, Schinazi RF, Chu CK, Anderson KS. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry. 41: 5150-62. PMID 11955063 DOI: 10.1021/Bi0121858 |
0.326 |
|
| Show low-probability matches. |
